Drug Repurposing in Oncology: Current Evidence and Future Direction

(E-pub Ahead of Print)

Author(s): Zhenzhan Zhang, Jianguang Ji*, Hao Liu*

Journal Name: Current Medicinal Chemistry

Become EABM
Become Reviewer
Call for Editor


Background: Drug repurposing, the application of known drugs and compounds with a non-oncology primary purpose, might be an attractive strategy to offer more effective treatment options to patients with cancer at a low cost and reduced time.

Methods: This review described a total of 10 kinds of non-oncological drugs from more than 100 mechanical studies as well as evidence from population-based studies. The future direction of repurposed drug screening was discussed by using patient-derived tumor organoids.

Results: Many old drugs showed previously unknown effects or off-target effects and can be intelligently applied for cancer chemoprevention and therapy. The identification of repurposed drugs needs to combine evidence from mechanical studies and population-based studies. Due to the heterogeneity of cancer, patient-derived tumor organoids can be used to screen the non-oncological drugs in vitro.

Conclusion: These identified old drugs could be repurposed in oncology and might be added as adjuvants and finally benefit patients with cancers.

Keywords: Drug repurposing, anti-cancer, population cohort, drug screening, organoid, cancer treatment.

Rights & PermissionsPrintExport Cite as

Article Details

(E-pub Ahead of Print)
DOI: 10.2174/0929867327999200820124111
Price: $95

Article Metrics

PDF: 134